Ms Contin (Morphine Sulfate)

Morphine sulfate, the active ingredient in Ms Contin, is an opioid analgesic presented as an extended‑release oral tablet for oral use. It is indicated for the management of moderate to severe chronic pain, cancer‑related pain, and postoperative pain that requires prolonged analgesia. It is marketed in the European Union and formulated to provide consistent plasma concentrations over a 12‑hour dosing interval.

GNH USA supplies Ms Contin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution across European and global markets.

Ms Contin, an opioid analgesic, is used to manage pain conditions where sustained relief is required.

- Moderate to severe chronic pain: provides continuous analgesia for long‑term pain management. - Cancer‑related pain: offers steady opioid effect to control malignant disease‑associated discomfort. - Post‑operative pain requiring prolonged analgesia: maintains analgesic coverage during recovery after surgery.

Morphine sulfate may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Constipation - Drowsiness - Dry mouth

Serious or Rare Side Effects: - Respiratory depression - Severe hypotension - Allergic reactions (e.g., anaphylaxis)

When prescribing Ms Contin, clinicians should consider several safety measures.

- Assess respiratory function: monitor for depression, especially after dose initiation or escalation. - Evaluate renal and hepatic function: adjust dosing in impairment. - Use the lowest effective dose: limit risk of dependence and adverse effects. - Avoid abrupt discontinuation: taper gradually to prevent withdrawal. - Store at ambient temperature: keep in original container, protect from moisture.

Ms Contin can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - CNS depressants (e.g., benzodiazepines, barbiturates): may cause profound sedation and respiratory depression. - MAO inhibitors: can precipitate hypertensive crisis or severe hypotension. - Other opioids: additive effect increasing risk of respiratory depression.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): increase morphine plasma concentrations. - CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce analgesic effect. - Anticholinergic agents: may worsen constipation.